Surgical Applications
Clinical Evidence
Surgical Applications

Clinical Evidence

RECOVER I Data After Post-Cardiotomy Cardiogenic Shock1

  • 94%

    survival at 1 month

  • 81%

    survival at 6 months

  • 75%

    survival at 1 year

Hemodynamic parameters improved immediately after Impella 5.0® placement, leading to an increase in mean cardiac index (CI) from 1.4 to 2.5 L/min/m2 and an increase in MAP from 71 mmHg to 83 mmHg.

Ongoing and Upcoming Clinical Trials

STEMI Door-to-Unloading (DTU) Pivotal Randomized Controlled Trial

This trial is randomizing patients undergoing treatment for ST-Elevation Myocardial Infarction (STEMI) who are not in cardiogenic shock to either 30 minutes of unloading with Impella CP® prior to reperfusion or standard of care with immediate PCI. 

Learn More

IMPACT: Impella Protected Cardiac Surgery Trial

This upcoming trial will evaluate the peri-operative use of Impella 5.5® with SmartAssist® in high-risk surgical patients.

Review Patient Management Best Practices

Learn more about measuring cardiac power output (CPO) and pulmonary artery pulsatility index (PAPi) and managing patients in the OR

References

  1. Griffith, B.P., et al. (2013). J Thorac Cardiovasc Surg, 145(2), 548-554.

NPS-1195

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].

The Protected PCI community
is now on HeartRecovery.com

Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
Explore Now